Skip to main content

Tagged With "trial"

Blog Post

Clinical Trial Will Test Whether Omalizumab Can Reduce Food Allergy Reactions

KFA News Team ·
While experimental desensitization strategies are available in research settings, people with food allergies must avoid known allergens and are advised to carry injectable epinephrine to prevent potentially life-threatening allergic reactions caused by accidental exposures. To help alleviate this risk, a new study to evaluate an experimental treatment for food allergy launched today.
Blog Post

Two Peanut Allergy Treatment Trials Move Forward

Kids With Food Allergies ·
Kids With Food Allergies is sharing these press releases from Aimmune Therapeutics and DBV Technologies to bring you the latest research news quickly. [PRESS RELEASE] Aimmune Therapeutics’ Pivotal Phase 3 PALISADE Trial of AR101 Meets Primary Endpoint in Patients With Peanut Allergy BRISBANE, Calif.– (BUSINESS WIRE) – Feb. 20, 2018 – Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced...
Blog Post Featured

The Future of Food Allergy: Developing New Treatments

KFA Medical Advisors ·
The future of food allergy: developing new treatments   by Michael H. Land, MD FAAAAI   I'm the father of a food allergic child. If you're reading this, I am guessing you or someone close to you has a food allergy. The minute you found out...
Comment

Re: The Future of Food Allergy: Developing New Treatments

LinzStein ·
Great overview! KFA- is there any additional info about the use of Allergen non-specific therapies for EoE? What about accupressure or homeopathics? Thank you!
Comment

Re: The Future of Food Allergy: Developing New Treatments

Kathy P ·
I haven't seen anything specific regarding those. You could check in the News & Research forum.
Comment

Re: The Future of Food Allergy: Developing New Treatments

franandpaul ·
Thanks for this great overview!
Comment

Re: The Future of Food Allergy: Developing New Treatments

sageone ·
This gives me hope that my child will eventually be allergy free and his life will not be in danger from a simple item of food! Thank you so much for this great article in layman terms so that we parents can understand it!
Comment

Re: The Future of Food Allergy: Developing New Treatments

EAH123 ·
What a great overview! Thank you!
Comment

Re: The Future of Food Allergy: Developing New Treatments

Jessica Dabler Martin ·
Fantastic overview of what is on the horizon. Thank you!
Comment

Re: The Future of Food Allergy: Developing New Treatments

Sandra Sebastian ·
Hi Michael, Very interesting for us to read as I have more than one grandchild with food allergies! Congratulations on all your accomplishments and studies. Love from us all, your old Oxford neighbour!
Comment

Re: The Future of Food Allergy: Developing New Treatments

cheymom ·
Welcome Jessica & Sandra! We are glad you found KFA. We hope you will join us on our Support Forums. We have several forums that may be of interest. Main Forum Babies, Toddlers & Preschoolers We even have a new forum for saving money! http://community.kidswithfooda...s-for-food-allergies We have a fantastic Food & Cooking forum Don't forget to check out our recipe section! Come join us! .
Comment

Re: The Future of Food Allergy: Developing New Treatments

Pearl ·
We are already doing Chinese Herbal medicine and seeing progress.
Blog Post

Dupixent® (Dupilumab) Shows Positive Results for Eosinophilic Esophagitis During Clinical Trial

KFA News Team ·
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced positive results from Part A of the pivotal Phase 3 trial evaluating Dupixent® (dupilumab) in patients 12 years and older with eosinophilic esophagitis (EoE). The trial met both of its co-primary endpoints, as well as all key secondary endpoints. Dupixent is the first and only biologic to show positive and clinically-meaningful results in this population as part of a Phase 3 trial.
Blog Post

FDA Approves Clinical Trial for Peanut Allergy Treatment Using Nanoparticles

KFA News Team ·
COUR Pharmaceuticals, a biotechnology company developing novel immune-modifying nanoparticles to treat immune disorders (CNPs), today announced the U.S. Food and Drug Administration (FDA) has accepted the company's Investigational New Drug (IND) application for evaluation of COUR's CNP-201 in a proof-of-concept (Phase 1 / 2) study in people who are allergic to peanuts.
Kids With Food Allergies
A Division of the Asthma and Allergy Foundation of America
1235 South Clark Street Suite 305, Arlington, VA 22202
Phone: 1-800-7-ASTHMA (1.800.727.8462)
-->
×
×
×
×